A multi-centre study comparing idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema

Submission date 18/07/2023	Recruitment status No longer recruiting	Prospectively registered
		<pre>Protocol</pre>
Registration date 13/08/2023	Overall study status Completed	Statistical analysis plan
		Results
Last Edited 05/09/2023	Condition category Respiratory	Individual participant data
		Record updated in last year
progressive lung di	udy aims Try fibrosis and emphys seases with limited trea	ema (CPFE) and idiopathic pulmonary fibrosis (IPF) are atment options. This study aimed to compare the E and those with IPF receiving anti-fibrotic agents.
Who can participate Patients with inters	e? stitial lung disease (ILD)	with IPF or CPFE.
What does the stud The study involved survival outcomes.		patients for a duration of 3 years and recording their
This study will inves		participating? two lung diseases and identify possible underlying participation as it was not an interventional study.
Where is the study Taichung Veterans	run from? General Hospital (Taiwa	an)
When is the study s June 2015 to Nove	tarting and how long is mber 2022	it expected to run for?
Who is funding the	study?	

Who is the main contact?

Dr Pin-Kuei Fu, paper199350@gmail.com

Taichung Veterans General Hospital (Taiwan)

Contact information

Type(s)

Principal investigator

Contact name

Dr Pin-Kuei Fu

ORCID ID

https://orcid.org/0009-0009-1843-4513

Contact details

1650 Taiwan Boulevard Sect. 4 Taichung City Taiwan 407219 +886 (0)4 2359 2525 paper199350@gmail.com

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

CE22228B

Study information

Scientific Title

Idiopathic pulmonary fibrosis with or without emphysema: a 3-year multi-centre study

Acronym

multiTaiCPFE2022

Study objectives

Patients with combined pulmonary fibrosis and emphysema (CPFE) treated with anti-fibrotic agents had survival outcomes similar to those of patients with idiopathic pulmonary fibrosis (IPF).

Ethics approval required

Ethics approval required

Ethics approval(s)

1. approved 12/05/2022, The Institutional Review Board of Taichung Veterans General Hospital (1650 Taiwan Boulevard Sect. 4, Taichung City, 407219, Taiwan; +886 (0)4 2359 2525; imsc@vghtc.gov.tw), ref: CE22228B

- 2. approved 13/07/2022, The Institutional Review Board of National Taiwan University, Yun-Lin Branch (No.579, Sec. 2, Yunlin Rd., Taichung City, 640, Taiwan; +886 (0)5 6330002 #8521; Y03511@ms1.ylh.gov.tw), ref: 202206026RINA
- 3. approved 30/04/2022, The Institutional Review Board of China Medical University Hospital (No. 2, Yude Rd., North Dist., Taichung City, 404327, Taiwan; +886 (0)4 2205 2121; imc@mail. cmuh.org.tw), ref: CMUH111-REC2-077
- 4. approved 22/06/2022, The Institutional Review Board of Chang Gung Medical Foundation (No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan; +886 (0)3 328 1200; syu2323@cgmh.org. tw), ref: 202200850B0
- 5. approved 23/08/2022, The Institutional Review Board of Chang Gung Medical Foundation (No. 5, Fuxing St., Guishan Dist., Taoyuan City, 333, Taiwan; +886 (0)3 328 1200; syu2323@cgmh.org. tw), ref: 202201260B0
- 6. approved 04/07/2022, The Institutional Review Board of E-DA hospital (No.1, Yida Road, Jiaosu Village, Yanchao District, Kaohsiung City, 82445, Taiwan; +886 (0)7 615 0011 #5765; ed111235@edah.org.tw), ref: EMRP-111-079
- 7. approved 05/08/2022, The Institutional Review Board of Ministry of Health and Welfare Taoyuan General Hospital (No. 1492, Zhongshan Rd, Taoyuan District, Taoyuan City, 330, Taiwan; +886 (0)3 3699721#3907; IHC@mail.tygh.gov.tw), ref: TYGH111040
- 8. approved 18/12/2018, Institutional Review Board of Taichung Veterans General Hospital (1650 Taiwan Boulevard Sect. 4, Taichung City, 407219, Taiwan; +886 (0)4 2359 2525; imsc@vghtc.gov.tw), ref: CE18325B

Study design

Retrospective observational cohort study

Primary study design

Observational

Study type(s)

Other

Health condition(s) or problem(s) studied

Patients with interstitial pulmonary fibrosis only (IPF) and patients with combined pulmonary fibrosis and emphysema (CPFE)

Interventions

The study involved following IPF and CPFE patients for a duration of 3 years and recording their survival outcomes.

Intervention Type

Other

Primary outcome(s)

3-year survival rate measured using patients' medical records

Key secondary outcome(s))

- 1. Pulmonary function measured using spirometer at baseline and every year for 3 years
- 2. Disease progression measured using Gender-Age-Physiology (GAP) score at baseline and every year for 3 years

Completion date

28/11/2022

Eligibility

Key inclusion criteria

- 1. Patients with a definitive diagnosis of interstitial lung disease by a pulmonologist and confirmed by high-resolution computed tomography (HRCT)
- 2. Passed the health insurance review to pay for the anti-pulmonary fibrosis medications

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Αll

Total final enrolment

275

Key exclusion criteria

- 1. Patients not fulfilling the criteria of interstitial lung disease
- 2. Patients not having health insurance to cover anti-fibrotic medications

Date of first enrolment

01/08/2018

Date of final enrolment

31/08/2022

Locations

Countries of recruitment

Taiwan

Study participating centre Taichung Veterans General Hospital

1650 Taiwan Boulevard Sect. 4

Taichung City Taiwan 407219

Study participating centre National Taiwan University, Yun-Lin Branch

No.579, Sec. 2, Yunlin Rd. Douliu City Taiwan 640

Study participating centre China Medical University Hospital

No. 2, Yude Rd., North Dist. Taichung City Taiwan 404327

Study participating centre Chang Gung Medical Foundation

No.5, Fuxing St., Guishan Dist. Taoyuan City Taiwan 333

Study participating centre E-DA hospital

No.1, Yida Road, Jiaosu Village, Yanchao Dist. Kaohsiung City Taiwan 82445

Study participating centre

Ministry of Health and Welfare, Taoyuan General Hospital

No. 1492, Zhongshan Rd, Taoyuan Dist. Taoyuan City Taiwan 330

Sponsor information

Organisation

Taichung Veterans General Hospital

ROR

https://ror.org/00e87hq62

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Taichung Veterans General Hospital

Alternative Name(s)

, TCVGH

Funding Body Type

Government organisation

Funding Body Subtype

Local government

Location

China

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analyzed during the current study will be available upon request from Dr Pin-Kuei Fu (yetquen@gmail.com)

IPD sharing plan summary

Available on request

Study outputs

Output type **Details** Date created Date added Peer reviewed? Patient-facing?

Participant information sheet 11/11/2025 11/11/2025 No Participant information sheet

Yes